Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Pfizer’s trading volume surged to $13.51 billion, more than doubling from the prior day. Despite the impressive spike in ...

A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...